Anti-CD38 monoclonal antibody
Showing 1 - 25 of >10,000
Multiple Myeloma Trial in France, Spain, United States (Daratumumab, Velcade, Pomalidomide)
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +11 more
-
Duarte, California
- +21 more
Jan 17, 2023
Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)
Recruiting
- Plasma Cell Myeloma
- Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 27, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Actinium Ac 225-DOTA-Daratumumab, Daratumumab,
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Actinium Ac 225-DOTA-Daratumumab
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston
Completed
- High Risk Myelodysplastic Syndrome
- +2 more
- Daratumumab
-
Houston, TexasM D Anderson Cancer Center
Nov 21, 2022
AL Amyloidosis Trial in Scottsdale, Jacksonville, Rochester (procedure, biological, other)
Not yet recruiting
- AL Amyloidosis
- Bone Marrow Biopsy
- +4 more
-
Scottsdale, Arizona
- +2 more
Jun 2, 2023
Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma, Secondary Amyloidosis Trial in Duarte (biological, drug, procedure, other)
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- +2 more
- Daratumumab
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 22, 2022
Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Tumor Trial in Houston (procedure,
Active, not recruiting
- Bladder Urothelial Carcinoma
- +4 more
- Biopsy
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Plasma Cell Myeloma Trial in Jacksonville (procedure, biological, drug)
Active, not recruiting
- Plasma Cell Myeloma
- Autologous Hematopoietic Stem Cell Transplantation
- +2 more
-
Jacksonville, FloridaMayo Clinic in Florida
Mar 25, 2022
Recurrent Plasma Cell Myeloma Trial in Houston (Daratumumab)
Recruiting
- Recurrent Plasma Cell Myeloma
- Daratumumab
-
Houston, TexasM D Anderson Cancer Center
Dec 22, 2021
Chronic Lymphocytic Leukemia Trial in Columbus (biological, drug, other)
Recruiting
- Chronic Lymphocytic Leukemia
- Daratumumab
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 24, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Small
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +4 more
- Daratumumab
- Ibrutinib
-
Jacksonville, FloridaMayo Clinic in Florida
Mar 22, 2022
Plasma Cell Myeloma Trial in Rochester (Bortezomib, Daratumumab, Dexamethasone)
Recruiting
- Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid
Completed
- Minimal Residual Disease
- +3 more
- Daratumumab
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Mar 2, 2022
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8 Trial in Houston (biological,
Active, not recruiting
- Prostate Adenocarcinoma
- +5 more
- Daratumumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Feb 25, 2022
Plasma Cell Myeloma Trial in Rochester (biological, drug, other)
Active, not recruiting
- Plasma Cell Myeloma
- Daratumumab
- +5 more
-
Rochester, MinnesotaMayo Clinic
Sep 8, 2022
Plasma Cell Myeloma Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)
Active, not recruiting
- Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Jan 10, 2023
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (biological, drug, other)
Recruiting
- Plasma Cell Myeloma
- +2 more
- Belantamab Mafodotin
- +4 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 10, 2022
Plasma Cell Myeloma, Secondary Amyloidosis Trial in Duarte, Nashville (procedure, biological, other, drug)
Recruiting
- Plasma Cell Myeloma
- Secondary Amyloidosis
- Autologous Hematopoietic Stem Cell Transplantation
- +3 more
-
Duarte, California
- +1 more
Dec 27, 2021
Immune Thrombocytopenia, Treatment Trial in Tianjin (CM313 Injection)
Not yet recruiting
- Immune Thrombocytopenia
- Treatment
- CM313 Injection
-
Tianjin, Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
Jan 12, 2023
Recurrent Plasma Cell Myeloma Trial in United States (Daratumumab, Dexamethasone, Pomalidomide)
Withdrawn
- Recurrent Plasma Cell Myeloma
- Daratumumab
- +2 more
-
Wichita, Kansas
- +4 more
Jun 13, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in United States (drug, biological, other)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +4 more
-
Des Moines, Iowa
- +8 more
Jan 12, 2023
Multiple Myeloma Trial in Rochester (procedure, biological, drug)
Not yet recruiting
- Multiple Myeloma
- Biospecimen Collection
- +12 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Sep 15, 2023
ISS Stage III Plasma Cell Myeloma, Plasma Cell Myeloma Trial in Rochester (procedure, drug, biological)
Not yet recruiting
- ISS Stage III Plasma Cell Myeloma
- Plasma Cell Myeloma
- Bone Marrow Aspiration and Biopsy
- +7 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 9, 2022
Multiple Myeloma Trial in Nanjing (HLX15, US-sourced DARZALEX®, CN-sourced DARZALEX® -)
Not yet recruiting
- Multiple Myeloma
- HLX15
- +2 more
-
Nanjing, Jiangsu, ChinaSir Run Run Hospital, Nanjing Medical University
Jan 9, 2023
Plasma Cell Myeloma, Renal Failure Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)
Recruiting
- Plasma Cell Myeloma
- Renal Failure
- Bortezomib
- +4 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Jun 13, 2022